Riskpilot← Back to searchSign inGet full accessXboXLab OY
OYActiveY-tunnus 3165497-1Aurinkokuja 6Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20201 employeeswww.xboxlab.fi
Revenue 2025
EUR 599K
+37% vs 2024
EBITDA margin
9.9%
+1383% vs 2024
Equity ratio
-50.8%
Financial strength
Net profit 2025
EUR 59K
+1383% vs 2024
| Revenue | EUR 599K | +37% |
| EBITDA | EUR 59K | +1383% |
| Net profit | EUR 59K | +1383% |
| Total assets | EUR 161K | +34% |
| Equity | EUR -82K | +42% |
| Employees | 1 | — |
Legal name
XboXLab OY
Y-tunnus number
3165497-1
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
16. lokakuuta 2020
Share capital
EUR 10 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Bolaget skall bedriva marknadsföring, försäljning och distribution, nationellt och internationellt, av laboratorieprodukter, diagnostiska produkter, farmacia, läkemedel och medicinteknisk utrustning, samt vidare tillhandahålla tjänster inom detta område, ävensom idka därmed förenlig verksamhet.
Address
Aurinkokuja 6
Phone
+358453222466
Email
info@xboxlab.fi
Website
www.xboxlab.fi
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 191 | 271 | 296 | 438 | 599 |
| Staff expenses | −122 | −111 | −112 | −105 | −115 |
| EBITDA | −66 | −24 | −66 | 4 | 59 |
| Depreciation & amort. | — | — | −0 | −0 | −0 |
| EBIT | −66 | −24 | −66 | 4 | 59 |
| Net financials | — | 0 | 0 | 0 | 0 |
| Profit before tax | −66 | −24 | −66 | 4 | 59 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −66 | −24 | −66 | 4 | 59 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 93 | 57 | 32 | 121 | 161 |
| Equity | −56 | 0 | 145 | −141 | −82 |
| Long-term debt | 101 | 21 | 146 | 173 | 173 |
| Short-term debt | 49 | 36 | 32 | 89 | 70 |
| Total debt | 149 | 57 | 178 | 262 | 243 |
EBITDA margin
9.9%
This company
15.8%
Market median
-37% vs market
20212025
Equity ratio
-50.8%
This company
38.2%
Market median
-233% vs market
20212025
Return on equity
5947900.0%
This company
18.4%
Market median
+32325443% vs market
20212025
Net profit margin
9.9%
This company
8.1%
Market median
+22% vs market
20212025
Asset turnover
3.71×
This company
1.12×
Market median
+231% vs market
20212025
Debt / equity
2.97×
This company
0.62×
Market median
-379% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2020-09-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
PB Deputy Member | Deputy Member | 2025 |
CK Deputy Member | Deputy Member | 2020 |
JM Chief Executive Officer | Chief Executive Officer | 2020 |
RT Deputy auditor | Deputy auditor | 2025 |
TA | Audit | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairperson | 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of XboXLab OY also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Blom | Deputy Member | 0 companies |
| Christer Karl Uno Lidén | Deputy Member | 0 companies |
| Jussi Matias Kontturi | Chief Executive Officer | 0 companies |
| Risto Tapani Mäkinen | Deputy auditor | 0 companies |
| Teemu Antero Laitinen | Audit | 0 companies |
| Henning Jansen | Chairperson | 0 companies |